<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - European Medicines Agency (conduct of pharmacovigilance activities in respect of medicinal products for human use) (A7-0476/2013 - Linda McAvan) - Wednesday, 16 April 2014</title><meta name="title" content="Verbatim report of proceedings - European Medicines Agency (conduct of pharmacovigilance activities in respect of medicinal products for human use) (A7-0476/2013 - Linda McAvan) - Wednesday, 16 April 2014" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2014 - Source: European Parliament" /><meta name="available" content="16-04-2014" /><meta name="sipade-leg" content="7" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - European Medicines Agency (conduct of pharmacovigilance activities in respect of medicinal products for human use) (A7-0476/2013 - Linda McAvan) - Wednesday, 16 April 2014" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-7-2014-04-16-ITM-015-10_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-7-2014-04-16-ITM-015-10_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-16-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-16-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-16-ITM-015-09_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-16-ITM-015-09_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-16-ITM-015-11_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-7-2014-04-16-ITM-015-11_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-7-2014-04-16_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-7-2014-04-16_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table>
                <table border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td align="left"><span class="contents">Procedure : </span><a class="ring_ref_link" href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2013/0222(COD)">2013/0222(COD)</a></td><td align="right"><table align="right" border="0" cellpadding="0" cellspacing="0"><tbody><tr><td><img src="/doceo/data/img/ring_tabs_left_doc_unselected.gif" height="19" width="4" alt="" /></td><td class="Tabs_doc_unselected"><img src="/doceo/data/img/ring_navi.gif" width="17" height="14" alt="" />Document stages in plenary</td><td valign="middle"><img src="/doceo/data/img/ring_tabs_right_doc_unselected.gif" height="19" width="4" alt="" /></td></tr></tbody></table></td></tr></tbody></table><table class="doc_box_header" border="0" cellpadding="0" cellspacing="0" width="100%"><tbody><tr><td class="ring_multiple_bg" valign="top" colspan="7">Document selected :
            <span class="ring_ref_selected_header">A7-0476/2013</span></td></tr><tr><td width="25%" valign="top" class="ring_step_bg1" nowrap="nowrap"><p class="ring_step_title">Texts tabled :</p>
                        <a href="/doceo/document/A-7-2013-0476_EN.html" class="ring_ref_link">A7-0476/2013</a><br />
                    </td><td width="15" style="background-image:url(/doceo/data/img/ring_bg1.gif)"><img src="/doceo/data/img/ring_flech1.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg2" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Debates :</p></td><td width="15" style="background-image:url(/doceo/data/img/ring_bg2.gif)"><img src="/doceo/data/img/ring_flech2.gif" width="13" height="22" border="0" alt="" /></td><td class="ring_step_bg3" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Votes :</p>
                        <a href="/doceo/document/PV-7-2014-04-16-ITM-014-08_EN.html" class="ring_ref_link">PV 16/04/2014 - 14.8</a><br />
                        <a class="ring_ref_selected">Explanations of votes</a><br />
                    </td><td width="19" style="background-image:url(/doceo/data/img/ring_bg3.gif)"><img src="/doceo/data/img/ring_flech3.gif" height="22" width="13" border="0" alt="" /></td><td class="ring_step_bg4" valign="top" width="25%" nowrap="nowrap"><p class="ring_step_title">Texts adopted :</p>
                        <a href="/doceo/document/TA-7-2014-0438_EN.html" class="ring_ref_link">P7_TA(2014)0438</a><br />
                    </td></tr></tbody></table><br />
            <table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Wednesday, 16 April 2014 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 15.10. European Medicines Agency (conduct of pharmacovigilance activities in respect of medicinal products for human use) (<a href="/doceo/document/A-7-2013-0476_EN.html">A7-0476/2013</a> - Linda McAvan) </td></tr></table>
<a name="3-103-841"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="bold">Schriftliche Erklärungen zur Abstimmung</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-103-871"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118860.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Claudette Abela Baldacchino (S&amp;D), </span></span>  <span class="italic">bil-miktub</span><span class="bold">. -</span> Huwa tajjeb li nieħdu passi biex fis-suq niggarantixxu mediċina li tkun sigura. Imma dan mhux biżżejjed. Irridu naraw kif nassiguraw li kulħadd ikollu aċċess għall-mediċina li jkollu bżonn. Bin-numru ta' nies li jgħixu fil-faqar jew f'riskju ta` faqar dejjem jiżdied, wisq nibża' li qiegħed jiżdied ukoll in-numru ta' dawk li jkollhom bżonn xi mediċina u jkollhom jiċċaħħdu minnha minħabba li ma jkollhomx il-mezzi biex jakkwistawha. Nemmen li kulħadd jaqbel li kull individwu għandu jkollu aċċess għall-kura li jkollu bżonn, imma bejn il-kliem u l-fatti hemm baħar jikkumbatti. Ejjew inkomplu nistinkaw biex anke f'dan il-qasam ikollna Ewropa aktar soċjali li tieħu ħsieb l-egħżeż ħaġa li għandu kull individwu - is-saħħa.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-103-901"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96976.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Luís Paulo Alves (S&amp;D), </span></span>  <span class="italic">por escrito</span>. <span class="bold">-</span> Aprovo o presente Relatório, considerando que a proposta da Comissão visa atribuir financiamento para a aplicação do novo Regulamento e da Diretiva da União Europeia sobre farmacovigilância, objeto de acordo em 2012. A nova lei atribui novas tarefas à Agência Europeia de Medicamentos e às autoridades nacionais competentes – entidades reguladoras nacionais – de cada Estado-Membro. Importa criar um mecanismo de financiamento, o mais brevemente possível, em particular porque a lei já entrou em vigor. Tomo ainda nota das novas tarefas da Agência que incluem nomeadamente o alargamento da base de dados Eudravigilance, de modo a abranger os medicamentos autorizados a nível nacional, e a inclusão de novas funções, nomeadamente uma secção pública a que as pessoas possam aceder em linha para pesquisar as reações adversas a medicamentos específicos.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-103-931"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96862.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sophie Auconie (PPE), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> La législation relative à la pharmacovigilance pour les médicaments est essentielle pour protéger les patients. Celle-ci a été révisée en 2010 puis en 2012, suite au scandale du Mediator. J’ai voté pour ce rapport, qui est équilibré dans sa formulation, afin que puisse entrer en vigueur au plus vite le mécanisme de financement nécessaire à la mise en œuvre de cette pharmacovigilance.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-103-961"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/97198.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Mara Bizzotto (EFD), </span></span>  <span class="italic">per iscritto. - </span>La proposta della Commissione riguarda il finanziamento relativo all'applicazione del nuovo regolamento e della nuova direttiva dell'UE sulla farmacovigilanza adottati nel 2012. La nuova normativa prevede nuove responsabilità sia per l'Agenzia europea per i medicinali, sia per le autorità nazionali competenti (i normatori nazionali in materia di medicinali) degli Stati membri. È importante istituire quanto prima un meccanismo di finanziamento, soprattutto perché la normativa è già entrata in vigore. Una revisione globale delle tariffe di farmacovigilanza è prevista per il prossimo anno, quando sarà possibile proporre una riorganizzazione completa dell'intero sistema. Sono d'accordo con il relatore che riconosce l'urgente necessità di creare un meccanismo di finanziamento e pertanto ho votato a favore di questa relazione.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-103-991"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112748.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Biljana Borzan (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Ovo izvješće se bavi reguliranjem odnosa između Europske agencije za lijekove (EMA), država članica i farmaceutskih tvrtki. Točnije, uređuje omjere plaćanja za ispitivanje i stavljanje na tržište novih lijekova. Države članice i EMA dijele odgovornost za sigurnost novih lijekova i pošteno je da se i prihodi koji se naplaćuju farmaceutskim tvrtkama dijele sukladno razini odgovornosti. </p>
<p class="contents">Potrebno je utvrditi jasne omjere dijeljenja prikupljenih sredstava i razdijeliti koje naknade se plaćaju kome. Na taj način će se izbjeći dvostruko naplaćivanje. Podržavam kompromis koji je postignut u pregovorima triju glavnih europskih institucija jer smatram da će reguliranje sustava naknada i plaćanja biti na korist poduzetnicima, državama članicama, ali i pacijentima koji će korisiti nove lijekove.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-021"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96742.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Jean-Luc Mélenchon (GUE/NGL), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> L’Agence européenne des médicaments est dotée, par ce texte, de nouvelles attributions en matière de surveillance du médicament et des risques qu’il induit. Ce projet de règlement lui donne de nouveaux moyens pour cela. Renforcer la pharmacovigilance au niveau européen est une bonne chose : en mutualisant et centralisant les données de tous les États membres, on augmente les chances de détecter des dangers liés à tel ou tel médicament. </p>
<p class="contents">Néanmoins, pour financer cette surveillance renforcée, la proposition de texte ne prévoit pas de redevances supplémentaires à payer par les industriels, mais un transfert des redevances perçues par les autorités nationales vers l’agence européenne. Cela risque de fragiliser tout le système de surveillance en fragilisant les agences nationales. C’est au contraire aux laboratoires de payer pour ce renforcement de la surveillance de leurs produits. Le texte prévoit également des réductions de redevances pour les médicaments les plus anciens déjà autorisés. Au regard de l'affaire du Médiator, on voit bien que c'est une erreur. La main des lobbies à décidément été trop lourde sur ce texte, je vote contre.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-051"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118859.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Roberta Metsola (PPE), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> A funding mechanism was urgently needed due to the implementation of the new EU Pharmacovigilance Regulation and Directive agreed in 2012. Moreover, the report removes unnecessary penalisations such as those affecting generics companies. I therefore supported this report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-081"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/118858.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marlene Mizzi (S&amp;D), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> I voted in favour of the European Medicines Agency report as I am in agreement.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-111"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96902.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Maria do Céu Patrão Neves (PPE), </span></span>  <span class="italic">por escrito. - </span>A proposta da Comissão visa atribuir financiamento para a aplicação do novo Regulamento e da Diretiva da UE sobre farmacovigilância, objeto de acordo em 2012. A nova lei atribui novas tarefas à Agência Europeia de Medicamentos (EMA) e às autoridades nacionais competentes (ANC) – entidades reguladoras nacionais – de cada Estado-Membro. No entanto, importa criar um mecanismo de financiamento o mais brevemente possível, em particular porque a lei já entrou em vigor. Votei favoravelmente por concordar com a necessidade urgente de criação de um mecanismo de financiamento e concordo com as alterações propostas pelo Parlamento à Comissão e que foram concebidas para permitir um rápido acordo. Prevê-se que uma revisão total das taxas da farmacovigilância tenha início no próximo ano, quando se puder propor uma profunda reformulação de todo o sistema. Contudo, neste período transitório, as propostas apresentadas são suficientes.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-141"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/112744.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Tonino Picula (S&amp;D), </span></span>  <span class="italic">napisan</span><span class="bold">. -</span> Kako se ovom uredbom postavljaju novi zadaci i nove odgovornosti Europskoj agenciji za lijekove poput stvaranja baze podataka svih autoriziranih proizvoda u Europskoj uniji i proširenje EudraVigilance baze prema javnosti kako bi zainteresirani građani mogli koristiti da pronađu primjerice kakve nuspojave koje određeni lijek može izazvati i slično, agenciji će trebati proširiti količinu novca kojom raspolaže, i procjena Komisije je 38,5 milijuna eura, dijelom i iz naknade koju bi plaćale farmaceutske kompanije, no podjela naknada na agenciju i zemlje članice je bila temom dugih pregovora te ovaj kompromis smatram privremeno dobrim rješenjem ukoliko se naknade budu temeljile na transparentnim i nezavisno revidiranim cijenama.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-171"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96755.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Sergio Paolo Francesco Silvestris (PPE), </span></span>  <span class="italic">per iscritto</span><span class="bold">. -</span> La nuova normativa sull'Agenzia europea per i medicinali include interessanti novità, quali l'ampliamento della banca dati Eudravigilance ai prodotti autorizzati a livello nazionale, la creazione di un archivio centrale dei rapporti periodici di aggiornamento sulla sicurezza e di una banca dati di tutti i prodotti autorizzati nell'UE, il monitoraggio delle pubblicazioni, il coordinamento delle valutazioni a livello dell'UE dei rapporti periodici di aggiornamento sulla sicurezza, la creazione di un portale europeo dei medicinali e l'organizzazione di audizioni pubbliche. </p>
<p class="contents">Queste nuove mansioni potrebbero arrivare a costare 38,5 milioni di EUR secondo la Commissione, da finanziare tramite le due fonti in questione. Il testo raggiunto durante il dibattito risponde alla necessità di creare in tempi brevi un meccanismo di finanziamento adeguato, motivo per cui ritengo che esso debba essere approvato senza ulteriori ritardi.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-201"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/119434.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Dubravka Šuica (PPE), </span></span>  <span class="italic">napisan</span><span class="bold">. - </span>Glavni zadatak Agencije jest zaštita i unapređenje zdravlja ljudi i životinja nadzorom nad lijekovima koji se koriste u medicinske i veterinarske svrhe. Ustrojena je kao mreža koja uz pomoć znanstvenih ustanova EU-a i država članica EFTA-e osigurava najvišu razinu kontrole lijekova u Europi. Blisko surađuje s partnerima u svijetu i pridonosi globalnoj harmonizaciji u području kontrole lijekova. </p>
<p class="contents">Važno je da mehanizam financiranja treba staviti na mjesto što je prije moguće, posebno zbog toga što je zakon već stupio na snagu. Prijedlog novih poslova treba provesti u što kraćem roku, a pokretanje web portala donijeti će dosta mogućnosti. Web portal će omogućiti pristup informacijama o lijekovima i nuspojavama koje oni nose i ono što je jako važno stvaranje baze podataka. </p>
<p class="contents">Sigurnosni sustav lijekova na razini EU-a dijele EMA- a i države članice, pa bi stoga i prikupljena sredstva trebala biti jednako podijeljena. Registrirani biljni i homeopatski lijekovi trebali bi u potpunosti izuzeti sve pristojbe da bi se potaknao njihov rad.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-231"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96920.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Kay Swinburne (ECR), </span></span>  <span class="italic">in writing</span><span class="bold">. -</span> EU pharmacovigilance legislation for medicinal products for human use was revised in 2010, in order to strengthen and rationalise the system for safety monitoring of medicines. It entered into force in July 2012 with additional amendments to pharmacovigilance legislation subsequently introduced following the 'Mediator' case (a drug developed by French drug company Servier for treating overweight diabetics that is estimated to have killed between 500-2,000 people before finally being banned in Europe). These recent changes have led to a widened remit for the European Medicines Agency (EMA), which has acquired pharmacovigilance competences also for nationally authorised medicines, in addition to reinforced competences for centrally authorised medicines. The report is proportionate an was endorsed by Conservative colleagues in committee, I therefore voted in favour of the report.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-261"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/29579.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marc Tarabella (S&amp;D), </span></span>  <span class="italic">par écrit</span><span class="bold">. –</span> La proposition de la Commission a pour objectif d'assurer le financement nécessaire à l'application du nouveau règlement et de la nouvelle directive européens sur la pharmacovigilance, adoptés en 2012. Ces textes confèrent de nouvelles attributions tant à l'Agence européenne du médicament (AEM) qu'aux autorités nationales compétentes, les agences en charge de la réglementation des médicaments dans chaque État membre. Il importe qu'un mécanisme de financement soit mis en place dans les meilleurs délais, principalement parce que la nouvelle réglementation est déjà entrée en vigueur.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="3-104-291"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/36281.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Silvia-Adriana Ţicău (S&amp;D), </span></span>  <span class="italic">în scris</span><span class="bold">. -</span> Am votat pentru propunerea de regulament privind taxele datorate Agenției Europene pentru Medicamente pentru desfășurarea de activități de farmacovigilență cu privire la medicamentele de uz uman. Veniturile Agenției Europene pentru Medicamente constau dintr-o contribuție a Uniunii și din taxele plătite de întreprinderi pentru obținerea și menținerea autorizațiilor de introducere pe piață ale Uniunii. Prezentul regulament se aplică taxelor pentru activitățile de farmacovigilență privind medicamentele de uz uman autorizate în Uniune în temeiul Regulamentului (CE) nr. 726/2004 și al Directivei 2001/83/CE și care sunt percepute de Agenția Europeană pentru Medicamente de la titularii de autorizații de introducere pe piață. De asemenea, prezentul regulament stabilește activitățile de farmacovigilență desfășurate la nivelul Uniunii pentru care sunt datorate agenției taxele, cuantumurile și modalitățile de plată ale respectivelor taxe, precum și nivelurile remunerației plătite de către agenție raportorilor și, după caz, coraportorilor pentru serviciile furnizate. Microîntreprinderile sunt scutite de plata oricărei taxe prevăzute în temeiul prezentului regulament. Taxele prevăzute în prezentul regulament ar trebui să fie transparente, echitabile și proporționale cu activitățile desfășurate. De asemenea, informațiile referitoare la aceste taxe ar trebui să fie publice.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
